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Table 1 Mean (standard deviation) cortical volumes (whole brain and each hemisphere) as a percentage of total intracranial volume in the total 
FTD cohort and TDP-43 subset
Frontal Temporal Parietal Occipital Cingulate Insula
Total FTD cohort: whole brain
AA 9.3 (0.9) 6.1 (0.8) 5.5 (0.4) 4.4 (0.4) 1.44 (0.14) 0.69 (0.12)
AG/GG 9.6 (1.0) 6.3 (0.8) 5.4 (0.6) 4.4 (0.4) 1.49 (0.14) 0.73 (0.11)
Total FTD cohort: left hemisphere
AA 4.6 (0.5) 2.9 (0.5) 2.7 (0.3) 2.2 (0.2) 0.68 (0.09) 0.34 (0.06)
AG/GG 4.8 (0.5) 3.0 (0.5) 2.7 (0.3) 2.2 (0.2) 0.72 (0.08) 0.36 (0.06)
Total FTD cohort: right hemisphere
AA 4.7 (0.5) 3.2 (0.4) 2.8 (0.2) 2.2 (0.2) 0.76 (0.08) 0.36 (0.07)
AG/GG 4.8 (0.6) 3.2 (0.4) 2.7 (0.3) 2.2 (0.2) 0.77 (0.09) 0.37 (0.06)
TDP-43 subset: whole brain
AA 9.4 (1.0) 5.8 (0.9) 5.4 (0.5) 4.4 (0.4) 1.42 (0.16) 0.69 (0.08)
AG/GG 9.8 (1.0) 6.0 (0.9) 5.5 (0.4) 4.4 (0.3) 1.49 (0.14) 0.72 (0.10)
TDP-43 subset: left hemisphere
AA 4.6 (0.5) 2.7 (0.6) 2.6 (0.3) 2.2 (0.2) 0.66 (0.10) 0.33 (0.05)
AG/GG 4.9 (0.5) 2.8 (0.6) 2.8 (0.3) 2.2 (0.2) 0.69 (0.08) 0.35 (0.06)
TDP-43 subset: right hemisphere
AA 4.8 (0.5) 3.1 (0.4) 2.8 (0.3) 2.2 (0.2) 0.76 (0.08) 0.36 (0.05)
AG/GG 4.9 (0.5) 3.2 (0.4) 2.8 (0.3) 2.2 (0.1) 0.79 (0.09) 0.37 (0.05)
FTD, frontotemporal dementia.
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The TMEM106B risk allele 
is associated with lower 
cortical volumes in a clinically 
diagnosed frontotemporal 
dementia cohort
INTRODUCTION
Frontotemporal dementia (FTD) is a 
neurodegenerative disease associated with 
impaired behaviour, language and motor 
function. Around a third of FTD is familial, 
with mutations in microtubule-associated 
protein tau (MAPT), progranulin (GRN) 
and chromosome 9 open reading frame 72 
(C9orf72) being the most common genetic 
causes. No other risk factors for FTD had 
been identified until a genome-wide asso-
ciation study of patients with the most 
common pathological form of FTD, fronto-
temporal lobar degeneration with TDP-43 
inclusions (FTLD-TDP), showed an associ-
ation with single nucleotide polymorphisms 
(SNPs) in a region encoding transmem-
brane protein 106b (TMEM106b).1 For 
the rs1990622 SNP the minor G allele was 
found to be less common in patients with 
FTLD-TDP than in a healthy control popu-
lation, that is, those expressing this allele 
were less likely to develop disease, and this 
effect was greatest in those with GRN muta-
tions (who have FTLD-TDP pathology).1 
Further studies of FTD cohorts have repli-
cated the finding in other GRN cohorts, 
in those with C9orf72 expansions (who 
also have FTLD-TDP pathology) and in 
one undifferentiated clinical FTD cohort.2 
3 Furthermore, neuroimaging studies have 
shown reduced left hemispheric grey matter 
volume in those carrying the major (risk) A 
allele within a healthy population cohort,4 
and reduced functional connectivity in 
those homozygous for the risk allele in a 
GRN cohort.5 In this study we investigate 
the association of the rs1990622 SNP with 
cortical volumes in a clinically diagnosed 
FTD cohort and a subset of cases with likely 
FTLD-TDP.
METHODS
The UCL FTD DNA cohort database was 
searched for those with volumetric MRI. 
Data were available from 198 patients 
with an FTD spectrum disorder: 87 with 
behavioural variant FTD (bvFTD), 46 
with non-fluent variant primary progres-
sive aphasia (nfvPPA), 43 with semantic 
variant PPA (svPPA), 6 with a primary 
progressive aphasia (PPA) syndrome not 
meeting criteria for any of the other PPA 
syndromes (called PPA-not otherwise spec-
ified here, abbreviated to PPA-NOS), 5 
with FTD associated with motor neurone 
disease (FTD-MND), 7 with corticobasal 
syndrome (CBS) and 4 with progres-
sive supranuclear palsy (PSP). Within 
this cohort, 76 individuals had definite 
or likely TDP-43 pathology: this group 
included cases with genetic mutations 
known to cause TDP-43 pathology (GRN 
(n=10), C9orf72 (n=17), dual GRN/
C9orf72 (n=1), TBK1 (n=1) and SQSTM1 
(n=2) mutations) and those with clinical 
syndromes associated with FTLD-TDP 
(FTD-MND and svPPA). Genotyping of 
the rs1990622 polymorphism in the total 
FTD cohort showed a frequency of AA 77 
(38.9%: 31 bvFTD, 19 nfvPPA, 20 svPPA, 
1 PPA-NOS, 1 FTD-MND, 2 CBS, 3 PSP), 
AG 90 (45.5%: 42 bvFTD, 21 nfvPPA, 
17 svPPA, 2 PPA-NOS, 3 FTD-MND, 
4 CBS, 1 PSP) and GG 31 (15.7%: 14 
bvFTD, 6 nfvPPA, 6 svPPA, 3 PPA-NOS, 
1 FTD-MND, 1 CBS, 0 PSP), and in 
the TDP-43 subset of AA 33 (43.4%), 
AG 34 (44.7%) and GG 9 (11.8%). The 
frequency within a UK control population 
of 5020 people from the Wellcome Trust 
Case Control Consortium was AA 1637 
(32.6%), AG 2485 (49.5%) and GG 898 
(17.9%). Using a homozygous protective 
allele model, there was no difference in 
the TDP-43 subset (Fisher’s exact test, 
p=0.225) or the total FTD cohort (Fish-
er’s exact test, p=0.450) compared with 
the control group, nor did allelic tests 
show significant differences between 
patients and controls. However, a homo-
zygous risk allele model in the TDP-43 
subset gave Fisher’s exact test, p=0.049 
compared with the control group, and 
in the total FTD cohort gave Fisher’s 
exact test, p=0.076 compared with the 
control group.
Cortical grey matter volumes (corrected 
for total intracranial volume) for the 
insula, cingulate, frontal, temporal, pari-
etal and occipital lobes in each hemisphere 
were generated from volumetric T1 MRI 
using a previously described method-
ology.6 Given the previous imaging studies 
and the results of the models above,4 
5 volumes were compared between the 
homozygous risk allele group (AA) and 
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those carrying at least one protective allele 
(AG/GG group) using non-parametric tests 
(Mann-Whitney U). These two groups did 
not significantly differ in age at MRI scan 
(total FTD cohort—AA: mean 63.6 (SD 
7.3) years, AG/GG: 63.2 (9.2); TDP-43 
subset—AA: mean 62.2 (6.7) years, AG/
GG: 63.9 (7.2)) or disease duration at 
time of MRI scan (total FTD cohort—AA: 
mean 4.9 (2.4) years, AG/GG: 4.9 (3.4); 
TDP-43 subset—AA: mean 4.9 (2.2) years, 
AG/GG: 5.0 (3.0)).
RESULTS
In the total FTD cohort, significantly lower 
volumes were present in the AA (risk, 
major allele) group compared with the 
AG/GG group in the frontal (p=0.009), 
temporal (p=0.029), cingulate (p=0.014) 
and insula (p=0.018) cortices (table 1).
As previous studies have shown an 
association of the rs1990622 polymor-
phism with decreased volumes in the left 
hemisphere,4 further analysis of cortical 
volumes within each hemisphere was 
performed. Significant differences between 
the two groups were shown only in the 
left hemisphere: in the frontal (p=0.003), 
temporal (p=0.019), cingulate (p=0.004) 
and insula (p=0.004) cortices (table 1).
In the TDP-43 subset, although similar 
or larger absolute differences in volume 
were seen in the AA group compared with 
the AG/GG group, a significant differ-
ence was only seen between the groups 
in the frontal lobe (p=0.044), with a 
trend to a difference in the cingulate 
(p=0.085) and insula (p=0.084) cortices. 
As with the clinical cohort, this was driven 
by an effect within the left hemisphere, 
with significant differences seen between 
groups in the frontal (p=0.013) and pari-
etal (p=0.037) cortices, and a trend to a 
difference in the cingulate (p=0.082) and 
insula (p=0.072) (table 1).
DISCUSSION
In a cohort of patients clinically diagnosed 
with FTD and also in a subset of patients 
with likely TDP-43 pathology, we show 
that homozygosity for the TMEM106B 
risk allele is associated with reduced grey 
matter volume in key cortical regions 
implicated in FTD. Consistent with 
previous research showing an effect of the 
TMEM106B risk allele on left hemisphere 
structures within the general population, 
decreased grey matter volumes were found 
in the left but not right hemisphere in both 
the total cohort and the TDP-43 subset.
Despite some studies showing no effect, 
overall, previous studies have shown that 
the effects of TMEM106B variants are 
seen in cases of FTD with FTLD-TDP 
(but not FTLD-tau), including those with 
mutations in GRN or C9orf72, as well 
as those without.2 Investigation of clini-
cally diagnosed cohorts has been variable, 
with only one study showing a positive 
effect. This variability is most likely to 
represent stronger effects in the gene 
mutation carriers and because of variable 
extent of TDP-43 pathology within each 
clinical cohort, with a greater number of 
FTLD-TDP cases resulting in a significant 
association within a cohort. In the cohort 
described here, at least 76/198 cases have 
probable or definite TDP-43 pathology, 
but this number is likely to be much higher 
as a substantial proportion of bvFTD 
cases and a smaller proportion of nfvPPA/
PPA-NOS cases will also have FTLD-TDP, 
hence the positive imaging findings in this 
study. Ideally, studies should be performed 
in postmortem confirmed cohorts, but in 
such a rare disease this is difficult.
TMEM106B is a glycoprotein critical 
for normal lysosomal function.2 Although 
its exact role in the pathogenesis of FTD 
remains unclear, studies have shown that 
TMEM106B appears to have an effect 
on the pathological burden of TDP-43 
pathology.2 It is unsurprising then that 
cell loss measurable as cortical grey matter 
atrophy on MRI is associated with the 
TMEM106B polymorphism. However 
further work is needed to understand the 
exact relationship and the extent of the 
effect in different pathological and genetic 
subtypes of FTD.
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